Published in Cancer Weekly, December 18th, 2007
"Based upon its impressive capabilities, we believe MaxCyte's cell loading technology can be an important component of our closed system," said Baek Chun Lee, Ph.D., Binex's Chairman. "Our immunotherapy product is currently undergoing review by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-12-18)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.